References of "NEUPREZ, Audrey"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailEfficacy and safety of currently marketed anti-osteoporosis medications
Reginster, Jean-Yves ULg; NEUPREZ, Audrey ULg; Dardenne, Nadia ULg et al

in Best Practice & Research. Clinical Endocrinology & Metabolism (in press)

During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally ... [more ▼]

During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally at all skeletal sites (i.e. spine, hip, and other non-spine). The armamentarium against osteoporosis includes anti-resorptive agents (i.e. bisphosphonates, selective estrogen receptor modulators and denosumab), bone-forming agents (i.e. peptides from the parathyroid hormone family) and one agent with a dual mechanism of action (i.e. strontium ranelate). All these medications combine anti-fracture efficacy with a reasonable benefit/risk profile. However, the choice of a particular chemical entity, in one individual patient is based on the knowledge and expertise of the physician. Prioritization of drugs should be based on the individual profile of the patient, the severity of osteoporosis and the specific contraindications, warnings and precautions of use of the various available medications. [less ▲]

Detailed reference viewed: 20 (10 ULg)
Full Text
Peer Reviewed
See detailDevelopment and validation of the French version of a tool assessing patient's expectations in lower limb osteoarthritis
NEUPREZ, Audrey ULg; Delcour, JP; Fatemi, F et al

in Journal of Orthopaedics (in press)

Detailed reference viewed: 30 (17 ULg)
Full Text
Peer Reviewed
See detailQuality of life benefits of knee arthroplasty for osteoarthritis
NEUPREZ, Audrey ULg; François, Garance ULg; KURTH, William ULg et al

in Osteoporosis International (2014), 25(2), 40

Detailed reference viewed: 31 (6 ULg)
Full Text
Peer Reviewed
See detailOsteonecrosis of the jaw in a male osteoporotic patient treated with denosumab
NEUPREZ, Audrey ULg; Coste, S; Rompen, Eric ULg et al

in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2014), 25

Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the ... [more ▼]

Osteonecrosis of the jaw (ONJ) is a clinical condition associated with long-term exposure to inhibitors of bone resorption, mainly bisphosphonates. Denosumab (DMab) is a human monoclonal antibody of the receptor activator of nuclear factor kappa-B ligand. It prevents osteoclast-mediated bone resorption and is widely prescribed for the management of postmenopausal osteoporosis. Whereas ONJ has already been reported in women treated with DMab, we report for the first time the development of ONJ, following tooth extraction, in a male patient treated for idiopathic osteoporosis with DMab. Due to the constant increase in DMab prescription, for the management of osteoporosis, in both genders, physicians should be made aware of this potential risk. [less ▲]

Detailed reference viewed: 46 (14 ULg)
Full Text
Peer Reviewed
See detailRisk of hip fracture in community-dwelling and institutionalized osteoporotic patients: A 3-year study.
Bruyère, Olivier ULg; Hiligsmann, Mickaël ULg; Zegels, Brigitte ULg et al

in International Journal of Gerontology (2013), 7(3), 167-70

Background and aims: It has been previously suggested that the incidence of hip fracture is higher among <br />people living in nursing homes than among community-dwelling people. However, it is not clear ... [more ▼]

Background and aims: It has been previously suggested that the incidence of hip fracture is higher among <br />people living in nursing homes than among community-dwelling people. However, it is not clear <br />whether this is a consequence of nursing home residency or of the greater age of the residents. We have <br />examined the relationship between the place of residence and hip fracture incidence, in a prospective 3- <br />year study. <br />Methods: Women from nine countries included in this study were part of the placebo group of <br />a randomized controlled trial having assessed the long-term effect of a new antiosteoporotic drug. All <br />women were osteoporotic and received placebo and vitamin D during the 3 years of follow-up. All the <br />institutionalized (nursing home, medical house) women (n ¼ 217) were included in this post hoc analysis <br />and three noninstitutionalized age- and country-matched controls were included (n ¼ 651). <br />Results: The mean (and standard deviation) age of the patients was 80.4 (5.6) years in the institutionalized <br />women and 80.2 (5.8) years in the noninstitutionalized women (p ¼ 0.87). After 3 years of followup, <br />37 fractures occurred: 12 (5.5%) in institutionalized women and 25 (3.8%) in noninstitutionalized <br />women. The difference between the two groups was not statistically significant (p ¼ 0.29). After <br />controlling for age, body mass index, femoral neck bone mineral density and prevalent nonvertebral <br />fracture, the residence status of the patient (institutionalized vs. noninstitutionalized) was not significantly <br />associated with hip fracture incidence (p ¼ 0.63). <br />Conclusions: We suggest that living in an institutionalized place is not an independent risk factor for hip <br />fracture for osteoporotic women receiving calcium and vitamin D. [less ▲]

Detailed reference viewed: 61 (23 ULg)
Full Text
Peer Reviewed
See detailComparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security and the new suggested FRAX criteria
Bruyère, Olivier ULg; Fossi, Martin; Zegels, Brigitte ULg et al

in Rheumatology International (2013), 33(4), 973-8

To assess the number of anti-osteoporosis treatments that would be reimbursed by the Belgian social security if either FRAX or the current criteria were used to determine access to reimbursement. This is ... [more ▼]

To assess the number of anti-osteoporosis treatments that would be reimbursed by the Belgian social security if either FRAX or the current criteria were used to determine access to reimbursement. This is a retrospective study based on data from 1,000 women randomly selected from an outpatient hospital specialized in bone metabolism in Belgium. Proportions of potentially refunded treatments between FRAX and current criteria were compared. Out of the 1,000 women files, 890 have sufficient information to assess FRAX . In Belgium, current criteria include a bone mineral density (BMD) T score below -2.5 at the lumbar spine, the femoral neck or the total hip and/or at least a prevalent vertebral fracture. Using these criteria, 167 women (18.8 %) would have access to reimbursement. Using the criteria based on the validated Belgian FRAX tool, only 116 women (13.0 %) would have access to reimbursement, meaning that access to reimbursement based on FRAX criteria would reduce by 30 % the anti-osteoporosis drug expenses covered by the national social security. Interestingly, only 65 women out of the 116 (56.0 %) selected with the FRAX criteria were also selected with the current criteria of the national social security. A substantial proportion of individuals that would potentially receive a reimbursement for their treatment using the FRAX criteria do not have access to any refund for their treatment with the current criteria. Since patients identified with the FRAX tool are those with the highest risk profile for future fractures, reappraisals of treatment reimbursement guidelines are expected in Belgium. [less ▲]

Detailed reference viewed: 35 (19 ULg)
Full Text
Peer Reviewed
See detailValidity of the French hip and knee replacement expectations surveys
NEUPREZ, Audrey ULg; François, Garance ULg; Delcour, JP et al

in Osteoporosis International (2013, April), 24(Suppl.1), 374

Detailed reference viewed: 39 (20 ULg)
Full Text
Peer Reviewed
See detailDéveloppement et validation de la version française d'un questionnaire traitant des attentes des patients dans l'arthrose des membres inférieurs
NEUPREZ, Audrey ULg; Delcour, JP; Fatemi, F et al

in Revue du Rhumatisme (2013), 80(S1), 181

Detailed reference viewed: 52 (8 ULg)
Peer Reviewed
See detailUsefulness of electrophysiology in muscle channelopathies
BETHLEN, Sarah ULg; NEUPREZ, Audrey ULg; Maystadt, Isabelle et al

Conference (2012, November 22)

Detailed reference viewed: 38 (7 ULg)
Full Text
Peer Reviewed
See detailRole of glucosamine in the treatment for osteoarthritis.
REGINSTER, Jean-Yves ULg; Neuprez, Audrey ULg; LECART, Marie-Paule ULg et al

in Rheumatology International (2012), 32(10), 2959-67

Over the last 20 years, several studies have investigated the ability of glucosamine sulfate to improve the symptoms (pain and function) and to delay the structural progression of osteoarthritis. There is ... [more ▼]

Over the last 20 years, several studies have investigated the ability of glucosamine sulfate to improve the symptoms (pain and function) and to delay the structural progression of osteoarthritis. There is now a large, convergent body of evidence that glucosamine sulfate, given at a daily oral dose of 1,500 mg, is able to significantly reduce the symptoms of osteoarthritis in the lower limbs. This dose of glucosamine sulfate has also been shown, in two independent studies, to prevent the joint space narrowing observed at the femorotibial compartment in patients with mild-to-moderate knee osteoarthritis. This effect also translated into a 50 % reduction in the incidence of osteoarthritis-related surgery of the lower limbs during a 5-year period following the withdrawal of the treatment. Some discrepancies have been described between the results of studies performed with a patent-protected formulation of glucosamine sulfate distributed as a drug and those having used glucosamine preparations purchased from global suppliers, packaged, and sold over-the-counter as nutritional supplements. [less ▲]

Detailed reference viewed: 67 (24 ULg)
Full Text
Peer Reviewed
See detailHealth-related quality of life after total knee or hip replacement for osteoarthritis: a 7-year prospective study
Bruyère, Olivier ULg; Ethgen, Olivier ULg; Neuprez, Audrey ULg et al

in Archives of Orthopaedic & Trauma Surgery (2012)

Objective To assess health-related quality of life (HRQOL) in a prospective study with 7 years of follow-up in 49 consecutive patients who underwent a total joint replacement because of osteoarthritis ... [more ▼]

Objective To assess health-related quality of life (HRQOL) in a prospective study with 7 years of follow-up in 49 consecutive patients who underwent a total joint replacement because of osteoarthritis. Methods Generic HRQOL was assessed with the shortform 36 (SF-36) and specific HRQOL with the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Results Out of the 39 subjects who have completed the 7 years of follow-up of this study, 22 (56.4 %) underwent a hip replacement surgery and the other 17 (43.6 %) a knee replacement. Six months after surgery, a significant improvement, compared to preoperative scores, was observed in two of the eight dimensions of the SF-36 (i.e. physical function and pain). The same dimensions, pain and physical function, at the same time, 6 months after surgery, measured by the WOMAC, showed a significant improvement as well, but there was no significant change in the stiffness score. From 6 months to the end of followup, changes in SF-36 scores showed a significant improvement in physical function (p = 0.008), role-physical (p = 0.004) and role-emotional (p = 0.01) while all scores of the WOMAC improved (p\0.001 for pain, p\0.001 for stiffness and p\0.01 for physical function). Conclusion The improvements observed in HRQOL at short term after surgery, are at least maintained over a 7-year follow-up period. [less ▲]

Detailed reference viewed: 48 (20 ULg)
Full Text
Peer Reviewed
See detailRadiological and clinical profil of osteoarthritic patients undergoing of total joint replacement
Neuprez, Audrey ULg; François, Garance ULg; Bruyère, Olivier ULg et al

in Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 693

Detailed reference viewed: 39 (15 ULg)
Full Text
Peer Reviewed
See detailAssessment of quality of life in patients undergoing total joint replacement for OA of the lower limb
Neuprez, Audrey ULg; François, Garance ULg; Bruyère, Olivier ULg et al

in Annals of the Rheumatic Diseases (2012, June), 71(Suppl.3), 693

Detailed reference viewed: 44 (10 ULg)
Full Text
Peer Reviewed
See detailRadiological and clinical profil of osteoarthritic patients undergoing of total joint replacement
Neuprez, Audrey ULg; François, Garance ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2012, March), 23(Suppl. 2), 129-130

Detailed reference viewed: 26 (8 ULg)
Full Text
Peer Reviewed
See detailRisk of hip fracture in community-dwelling and institutionalized osteoporotic patients: a 3-year study
Bruyère, Olivier ULg; Hiligsmann, Mickaël ULg; Zegels, Brigitte ULg et al

in Osteoporosis International (2011, March), 22(Suppl.1), 332-333

Detailed reference viewed: 23 (7 ULg)